Kornimate/medical-research-clean huggingface dataset:
arthroscopic treatment of meniscal lesions on healthy meniscus in children and adolescents

Conditions: Knee Injuries

Summary: meniscal lesions are common in pediatrics and mainly affect adolescents. these lesions can jeopardize the functional prognosis of the knee in the short, medium or long term if they are not well managed. more precisely, it is a question of determining whether arthroscopic repair of isolated meniscal lesions in children gives good results and what factors influence them, with the aim of improving the care of children suffering from meniscal lesions. the treatment of meniscal lesions comes down to either conservative or restorative treatment or non-conservative treatment by meniscectomy. for most authors, the treatment of meniscal lesions must remain restorative through meniscal suture, leaving no room for meniscectomy. the open approach has given way to the arthroscopic approach which, according to the literature, is the gold standard. meniscal lesions are varied and therefore there are numerous therapeutic procedures. therapeutic indications are precise but the results of the treatments remain differently assessed depending on the studies; studies evaluating the results of treatment in the pediatric population are few in number. based on this observation, the present study aims to describe the results of repairs of meniscal lesions in pediatric traumatology.


Eligibility criteria:
inclusion criteria: * minor subject under 18 years old * subject operated on at strasbourg university hospital for repair of lesions on healthy meniscus during the period from february 1, 2010 to september 30, 2022. * absence of written opposition in the medical file of the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes. exclusion criteria: * presence of opposition from the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes. * subject with lesion on discoid meniscus * incomplete or unusable clinical file

Keywords: knee injuries meniscus pediatric traumatology
study of the native outflow tract transcatheter pulmonary valve (tpv)

Conditions: Congenital Heart Disease; Tetralogy of Fallot

Summary: the purpose of this early feasibility study is to determine how a new transcatheter pulmonary valve will move and perform once implanted in the right ventricular outflow tract.

medtronic, inc. is in the process of developing a novel transcatheter device option for patients with congenital heart disease, without right ventricle-to-pulmonary artery conduits, called the native outflow tract transcatheter pulmonary valve. given limitations in the animal model to confirm device boundary conditions, this feasibility study is proposed to characterize that information as well as evaluate safety, procedural feasibility and performance data to be used for future development of the device.

Eligibility criteria:
inclusion criteria: * subject has pulmonary regurgitation as per one or more of the following criteria: severe pulmonary regurgitation as measured by doppler echocardiography, or pulmonary regurgitant fraction ≥ 30% as measured by cardiac magnetic resonance imaging * clinical indication for surgical placement of a rvot conduit or bioprosthetic pulmonary valve per one or more of the following criteria: subject is symptomatic secondary to pulmonary insufficiency (e.g. exercise intolerance, fluid overload) as classified by the investigator, or right ventricular end diastolic volume (rvedv) ≥ 150 ml/m2 * subject is willing to consent to participate in the study and will commit to completion of all follow-up requirements exclusion criteria: * anatomy unable to accommodate a 25 fr delivery system * obstruction of the central veins * clinical or biological signs of infection including active endocarditis * indicated for intervention of stenosis of the branch pulmonary arteries at time of implant * positive pregnancy test at baseline (prior to ct angiography and again prior to implant procedure) in female subjects of child bearing potential * patients with right ventricular outflow tract obstruction (rvoto) lesions surgically treated with a right ventricle-to-pulmonary artery conduit implant * a major or progressive non-cardiac disease (e.g. liver failure, renal failure, cancer) that results in a life expectancy of less than one year * planned implantation of the native outflow tract tpv in the left heart * rvot anatomy or morphology that is unfavorable for anchoring * known allergy to aspirin, heparin, or nickel * echocardiographic evidence of intracardiac mass, thrombus, or vegetation * pre-existing prosthetic heart valve or prosthetic ring in any position * patient is currently enrolled in another investigational device or drug trial that may influence the outcome of this trial.

Keywords: pulmonary valve congenital heart disease transcatheter pulmonary valve percutaneous pulmonary valve
optimal duration of dual antiplatelet therapy after stent-assisted coiling

Conditions: Aneurysm Cerebral; Endovascular Procedures

Summary: comparison of duration of dual antiplatelet therapy after stent-assisted coiling of unruptured intracranial aneurysms

the purpose of this study is to compare the incidence of thromboembolic and hemorrhagic complications between 1 and 18 months after stent-assisted coiling according to the duration of use of dual antiplatelet agents (6 months versus 12 months) after stent-assisted coiling of unruptured intracranial aneurysms to determine the optimal duration of use of dual antiplatelet agents.

Eligibility criteria:
inclusion criteria: * subjects over 19 years old * subjects with modified rankin scale (mrs) ≤ 2 * subjects with unruptured intracranial aneurysms * subjects with appropriated aspirin and clopidogrel reaction units after dual antiplatelet preparation (100 mg of aspirin and 75 mg of clopidogrel) for at least 5 days before procedure \[measured using verifynow\] 1. aspirin reaction unit (aru) \< 550 2. p2y12 reaction unit (pru): 85\~219 * subjects who agreed to this study (with informed consent) exclusion criteria: * subjects with neurological deficits (mrs ≥ 3) * subjects with an allergic reaction to antiplatelets (aspirin and clopidogrel) or contrast * subjects with a high risk of hemorrhage such ich or severe gastric ulceration * subjects with coagulopathy * subjects with thrombocytopenia (\<100,000/mm3) * subjects with liver diseases (\> 100iu/l of aspartate aminotransferase or alanine aminotransferase) * subjects with renal diseases (\> 2mg/dl of serum creatinine) * subjects with underlying diseases that need to maintain dual antiplatelet drugs or anticoagulants. * subjects with a high risk of strokes (atrial fibrillation, over 70% cerebral artery stenosis or cerebral artery occlusion, moyamoya disease, vascular malformations, etc) * subjects with uncontrolled congestive heart failure or angina * subjects with malignant tumors * subjects with a positive pregnancy test (serum or urine) * subjects who are unconscious at the time of diagnosis. * subjects who are unable to complete the required follow-ups * subjects with life-threatening diseases * subjects with medical conditions with a life expectancy of less than two years * subjects who are determined to be disqualified by researchers

Keywords: dual antiplatelet cerebral aneurysm coil embolization stent
early post-marketing study of eliquis (apixaban)

Conditions: Non-valvular Atrial Fibrillation (NVAF)

Summary: the primary objective of the study is to identify and describe any suspected (aes) in all patients with nvaf treated with apixaban, as a request of the national center of pharmacovigilance (cnfv) in mexico.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * all patients with nvaf at the sentinel site for the cnfv in mexico who received at least 1 dose of apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period exclusion criteria: * subjects who received apixaban as part of a clinical trial * subjects who received apixaban for any indication other than local approval (ie, to reduce the risk of stroke and systemic embolism in patients with nvaf)
safety study in volunteers from 16 to 65 years of age: fsme immun new vs. encepur

Conditions: Encephalitis, Tick-borne

Summary: the purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (tbe) vaccine fsme-immun new (5 consecutive lots) in comparison to another licensed tbe vaccine (encepur® adults, with polygeline) (2 lots) in healthy volunteers aged 16 to 65 years.


Eligibility criteria:
inclusion criteria: male and female volunteers were eligible for participation in this study if they: * were 16 years (from the 16th birthday) to 65 years (to the last day before the 65th birthday) old * were clinically healthy * had a negative pregnancy test at the first medical examination, if female and capable of bearing children * agreed to employ adequate birth control measures for the duration of the study, if female and capable of bearing children * provided written informed consent * for volunteers under 18 years of age - written informed consent of the parents / guardian was available * agreed to keep a volunteer diary exclusion criteria: * history of any previous tbe vaccination * history of tbe infection or show evidence of latent tbe infection (as demonstrated by screening elisa \> 126 vieu/ml) * history of allergic reactions, in particular to one of the components of the vaccine * previously received volume substitution with a product containing polygeline (stabilizer in encepur) * received antipyretics within 4 hours prior to the first tbe vaccination * suffer from a disease that cannot be effectively treated or stabilized * suffering from a disease (e.g. autoimmune disease) or were undergoing any form of treatment that could be expected to influence immunological functions * suffering from chronic, degenerative and/or inflammatory disease of the central nervous system * using any immunosuppressive drugs (e.g. local or systemic corticosteroids, chemotherapeutics) * had a known or suspected problem with drug or alcohol abuse (\> 4 liters wine / week or equivalent level of other alcoholic beverages) * had donated blood or plasma within one month of the study start * had received banked blood or immunoglobulins within one month of study entry * known to be hiv positive (a special hiv test was not required for the purpose of the study) * suffering from a febrile illness at study entry * history of vaccination against yellow fever and / or japanese b encephalitis * participating simultaneously in another clinical trial * if female: pregnant or breast feeding
a study to evaluate the effect of funk it cycle bites on pms

Conditions: Premenstrual Syndrome

Summary: this is a virtual, open-label, single-group study that will last 4 menstrual cycles. all participants will complete a questionnaire at the end of their first period after enrolling (baseline/non-intervention cycle 1), then proceed to take the product daily and complete questionnaires at the end of their next 3 periods (intervention cycles 1, 2, and 3). the study will involve 30 female participants with regular menstrual cycles who experience pms. questionnaires will be used to monitor menstrual pain/cramps, energy levels, mood, and hormonal acne experienced before and during the menstrual cycle. likert scale responses will be statistically compared from baseline to each check-in. participant responses on product feedback will be presented as % scores.


Eligibility criteria:
inclusion criteria: * female aged 18-40 * have a regular menstrual cycle (every 21-35 days). * suffer from mild to moderate menstrual pain. * may experience mood swings and/or hormonal acne related to the menstrual cycle. * otherwise generally healthy. * willing to consume the test product with a ginger flavor. * willing to refrain from taking any other supplements or prescription medications that may target the menstrual cycle or premenstrual syndrome (pms) symptoms throughout the study period. * willing and able to adhere to the study protocol, including taking supplements at the required times and completing questionnaires via the technology portal. * able to communicate in english. * participants must provide written informed consent (icf). exclusion criteria: * any unstable or uncontrolled medical or psychiatric illness. * any uncontrolled chronic disease or condition that would prevent full participation in the study protocol. * a history of polycystic ovary syndrome (pcos), endometriosis, premenstrual dysphoric disorder (pmdd), or undiagnosed vaginal bleeding. * are taking hormonal contraception or exogenous sex hormones (estrogen, testosterone, progesterone), or have taken hormonal contraception or exogenous hormones in the past 6 months. * are taking any prescription medication or supplements that target the menstrual cycle or pms symptoms. * are pregnant, breastfeeding, trying to become pregnant, or have been pregnant in the past 12 months. * have any known severe allergic reactions, or any allergies of any severity to any of the test product's ingredients.
emg-controlled game to retrain upper extremity muscle activation patterns following stroke

Conditions: Stroke

Summary: the purpose of this study is to develop and test if upper limb task practice and muscle activity training improve upper limb function in stroke survivors. participants will be asked to come to the laboratory 23 times (approximately 3 times a week) over 2.5 months to receive upper limb task practice, muscle activity training, and/or upper extremity functional assessments.

the purpose of this study is to develop and test if upper limb task practice and muscle activity training improve upper limb function in stroke survivors. participants will be asked to come to the laboratory 23 times (approximately 3 times a week) over 2.5 months to receive upper limb task practice, muscle activity training, and/or upper extremity functional assessments.

Eligibility criteria:
inclusion criteria: * 18+ years old * stroke more than 6 months ago * moderate unilateral upper limb impairment * cognitive ability to participate in the study procedure * ability to see the full computer screen exclusion criteria: * concurrent upper limb rehabilitation * inability to voluntarily contract muscles of at least 2 upper limb muscle groups, prohibiting participation in training * change in spasticity medication or botulinum toxin injection in the upper limb within 3 months prior to or during enrollment * total sensory loss * comorbidity (e.g., orthopaedic or premorbid neurologic condition) that limit upper limb movement and/or participation in the intervention * language barrier or cognitive impairment that precludes providing consent

Keywords: upper limb rehabilitation emg muscle activation pattern serious game virtual reality biofeedback
a study to observe treatment patterns and outcomes in patients with her2-positive unresectable locally advanced or metastatic breast cancer

Conditions: Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

Summary: this observational disease registry is a prospective, national, non-interventional study designed to enroll participants who have received an initial diagnosis of unresectable, locally advanced (la) or metastatic breast cancer (mbc), up to 6 months prior to registry enrolment. these participants will be prospectively followed for at least 5 years after study enrolment to evaluate their anti-cancer treatments. data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.


Eligibility criteria:
inclusion criteria: - initially diagnosed with her2-positive unresectable la/mbc no more than 6 months prior to enrolment, although they can have received anti-cancer treatment during that time exclusion criteria: there are no exclusion criteria for entry into this study.
investigation of genetic risk of metabolic syndrome in company employee (ngk study)

Conditions: Healthy; Metabolic Syndrome X; Hyperlipidemia; Hypertension; Diabetes Mellitus

Summary: the metabolic syndrome is a highly prevalent disorder, which causes atherosclerotic cardiovascular disease and is closely associated with insulin resistance. the alteration of the secretion of adipocytokines from accumulated visceral adipose tissue in the obese induces insulin resistance. the purpose of this study is to identify gene polymorphisms that confer susceptibility to the metabolic syndrome and to make up a new health guidance program based on genetic risk assessment. about 25% of male employees over 45 years old in a certain company are diagnosed with the metabolic syndrome in medical examination. we, the researchers at nagoya university, will analyze gene polymorphism and various biomarkers of over 3500 company employees.


Eligibility criteria:
inclusion criteria: * healthy subjects who work for a certain company

Keywords: insulin resistance adipocytokine metabolic syndrome diabetes
the concept of pain treatment in patients with gunshot and mine-explosive wounds and to develop an algorithm for analgesia at the stages of treatment

Conditions: Chronic Pain

Summary: in 82.1% of cases it is not possible to achieve a positive result of pain treatment

the concept of pain treatment in patients with gunshot and mine-explosive injuries and the developed pain relief algorithm at the stages of treatment will have an impact on the results of pain treatment in this category of patients.

Eligibility criteria:
inclusion criteria: * the presence of gunshot and mine-explosive injuries exclusion criteria: * absence of gunshot and mine-explosive injuries

Keywords: concept of pain treatment, pain, wounds, stages of treatment
artibiome: observational study on the effect of hiv and art on gut microbiome

Conditions: HIV Infections

Summary: antiretroviral treatment for hiv has allowed patients to have undetectable viral load indefinitely. despite that, hiv infection has become a chronic inflammatory disease, with increased mortality. this pro-inflammatory state is in part explained by the dysbiosis of intestinal bacterial populations. however, little is known on the impact of the antiretroviral treatment on this population and very few studies have evaluated these alterations. the aim of this study is to study microbiome on healthy patients and hiv-infected patients exposed to antiretroviral treatment with integrase strand transfer inhibitors.


Eligibility criteria:
inclusion criteria: * willing to sign consent form * men with an age \>18 years * engagement in insertive or receptive anal intercourse with another men \*exclusion criteria: * previous history of art exposure * use of antibiotics in the past 3 months * previous history of inflammatory bowel disease, autoimmune disease or cirrhosis.
outcame of cases with hemolytic uremic syndrome attending assiut university child hospital

Conditions: Hemolytic Uremic Syndrome of Childhood

Summary: diarrhea-associated hemolytic uremic syndrome (d+hus) is defined as a prodrome of enteritis followed by thrombocytopenia (\< 150,000/mm3), microangiopathic hemolytic anemia, and signs of variable degrees of renal damage (increase in serum cr, proteinuria, and/or hematuria) . our aim is to detect the most reliable early predictors of poor prognosis to identify children at major risk of bad outcome who could eventually benefit from early specific treatments.

the disease is caused predominantly by shiga toxin-producing enterohemorrhagic escherichia coli (stec) and is one of the most common etiologies of acute kidney injury (aki) and an important cause of acquired chronic kidney disease in children \[2\]. the incidence of huc tends to parallel the seasonal fluctuation of e.coli o175 : h7 infection which peaks between june \& september. nowadays, the incidence increases and is typically observe in infants and children, especially those aged 6 months to 4 years. a complicated disease course is defined as the development of one or more of the following manifestations: neurological dysfunction, severe bowel injury, pancreatitis, hemodynamic instability (symptomatic hypotension, multi-organ failure), cardiac (congestive heart failure, myocarditis, pericarditis, arrhythmia) or pulmonary involvement (pulmonary edema, acute respiratory distress syndrome), hematologic complications (hemorrhage), and death \[1\]. many laboratory and clinical markers upon admission have been associated to severe forms of the disease, including high initial leukocyte and hematocrit levels, major extrarenal complications, dehydration and recently, the blood urea nitrogen (bun) to serum creatinine (cr) ratio \[1\], \[4-6\]. treatment of d+hus remains supportive; thus, early identification of high-risk patients can optimize their management \[1-3\].

Eligibility criteria:
inclusion criteria: * all patients less than 18 years diagnosed with hemolytic uremic syndrome
changes in speed, endurance and balance in women patients with multiple sclerosis after 4 & 8 weeks of aquatic exercise training

Conditions: Multiple Sclerosis; Aquatic; Exercise

Summary: background: it has been shown that adults with multiple sclerosis (ms) have less leg strength than their peers, as well as impaired balance, which has led to an increased prevalence of falls in this population.the purpose of this study was to assess the effects of 8-weeks aquatic exercise training in balance, endurance and speed in women with ms. methods: in this semi-experimental study, 32 women with clinically-definite relapsing-remittent ms who were registered through the isfahan ms association volunteered for this study. they randomly selected an aquatic exercise (n = 17) and control (n = 15) groups. aquatic exercise group completed a 8-week aquatic exercise training program consisted of three sessions per week, each session lasting 45 to 60 minutes 50 to 75 percent of their maximum heart rate reserve on 20-25 degree centigrade's, whereas the control group was instructed to maintain their current lifestyle. the balance of angry was surveyed with using of berg analyze, speed and endurance 6 minutes walking test before starting of exercise program and after 4 weeks and at the end of 8 weeks was analyzed. the obtained data's were analyzed using analysis of variance with repeated measures.


Eligibility criteria:
inclusion criteria: * all women diagnosis of clinically or laboratory supported ms, a minimum time of two years since the diagnosis was made, no relapse within the 4 weeks preceding baseline, ability to participate in regular exercise sessions. exclusion criteria: * patients were excluded from the study if they had a relapse during the intervention period, and had a disease preventing their participation (e.g. cardiovascular, respiratory or skeletal diseases).